Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)

被引：19

作者：

Anam, Mahvish ^{[1
]}

Maharjan, Shrinkhala ^{[1
]}

Amjad, Zainab ^{[1
]}

Abaza, Abdelrahman ^{[2
]}

Vasavada, Advait M. ^{[1
]}

Sadhu, Akhil ^{[3
]}

Valencia, Carla ^{[1
]}

Fatima, Hameeda ^{[1
]}

Nwankwo, Ijeoma ^{[1
]}

机构：

[1] Calif Inst Behav Neurosci & Psychol, Internal Med, Fairfield, CA 94534 USA

[2] Calif Inst Behav Neurosci & Psychol, Pathol, Fairfield, CA USA

[3] Calif Inst Behav Neurosci & Psychol, Family Med, Fairfield, CA USA

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2022年 / 14卷 / 12期

关键词：

systematic review; glp-1 receptor agonists; safety; efficacy; obesity treatment; semaglutide; glucagon like peptides; ASSOCIATION; MANAGEMENT;

D O I：

10.7759/cureus.32610

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Obesity is a major health problem worldwide resulting in numerous health conditions such as heart disease, stroke, type 2 diabetes (T2D), and certain types of cancer which are among the leading causes of premature preventable deaths. Recently, glucagon like peptide-1 receptor agonists (GLP-1 RA) has been identified as the most promising intervention in treating obesity. Our systematic review aims to analyze the efficacy of semaglutide, a GLP-1RA in treating obesity. We searched PubMed, Science Direct, and Google Scholar databases to review and distill full-text articles based on the eligibility criteria and involved 12 papers of clinical trials. The review found that semaglutide is safe and effective in treating obesity, and complications reported were primarily gastrointestinal events. Further exploration with more number of clinical trials involving greater sample size and lengthier time of follow-up is essential to determine its efficacy and safety in a diverse group of individuals who are overweight or obese and the dose required along with the duration of treatment.

引用

页数：9

共 28 条

[1] Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial [J].

Ahmann, Andrew J. ;

Capehorn, Matthew ;

Charpentier, Guillaume ;

Dotta, Francesco ;

Henkel, Elena ;

Lingvay, Ildiko ;

Holst, Anders G. ;

Annett, Miriam P. ;

Aroda, Vanita R. .

DIABETES CARE, 2018, 41 (02) :258-266

[2]

[Anonymous], 2021, National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes, National Health Statistics Reports

[3]

[Anonymous], 2022, Defining Adult Overweight Obesity

[4] PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes [J].

Aroda, Vanita R. ;

Rosenstock, Julio ;

Terauchi, Yasuo ;

Altuntas, Yuksel ;

Lalic, Nebojsa M. ;

Morales Villegas, Enrique C. ;

Jeppesen, Ole K. ;

Christiansen, Erik ;

Hertz, Christin L. ;

Haluzik, Martin .

DIABETES CARE, 2019, 42 (09) :1724-1732

[5] Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity [J].

Blundell, John ;

Finlayson, Graham ;

Axelsen, Mads ;

Flint, Anne ;

Gibbons, Catherine ;

Kvist, Trine ;

Hjerpsted, Julie B. .

DIABETES OBESITY & METABOLISM, 2017, 19 (09) :1242-1251

[6] Depression in association with severe obesity - Changes with weight loss [J].

Dixon, JB ;

Dixon, ME ;

O'Brien, PE .

ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (17) :2058-2065

[7] PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis [J].

Haddaway, Neal R. ;

Page, Matthew J. ;

Pritchard, Chris C. ;

McGuinness, Luke A. .

CAMPBELL SYSTEMATIC REVIEWS, 2022, 18 (02)

[8] Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes [J].

Husain, Mansoor ;

Birkenfeld, Andreas L. ;

Donsmark, Morten ;

Dungan, Kathleen ;

Eliaschewitz, Freddy G. ;

Franco, Denise R. ;

Jeppesen, Ole K. ;

Lingvay, Ildiko ;

Mosenzon, Ofri ;

Pedersen, Sue D. ;

Tack, Cees J. ;

Thomsen, Mette ;

Vilsboll, Tina ;

Warren, Mark L. ;

Bain, Stephen C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (09) :841-851

[9] FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade [J].

Idrees, Zarwa ;

Cancarevic, Ivan ;

Huang, Li .

CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)

[10] Role of glucagon-like peptide 1 receptor agonists in management of obesity [J].

Isaacs, Diana ;

Prasad-Reddy, Lalita ;

Srivastava, Sneha Baxi .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (19) :1493-1507

← 1 2 3 →